Share on StockTwits

Cyclacel Pharmaceuticals (NASDAQ:CYCC) issued its quarterly earnings data on Tuesday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08, ARN reports.

Shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) traded up 0.93% during mid-day trading on Tuesday, hitting $3.24. 65,398 shares of the company’s stock traded hands. Cyclacel Pharmaceuticals has a 52-week low of $2.75 and a 52-week high of $5.50. The stock has a 50-day moving average of $3.16 and a 200-day moving average of $3.42. The company’s market cap is $73.5 million.

Cyclacel Pharmaceuticals, Inc (NASDAQ:CYCC) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders.

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.